Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
A Phase I Study of Safety, Pharmacokinetics and Efficacy of HMPL-523 With Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukemia
Sponsor: Hutchison Medipharma Limited
Terminated
Slow Enrollment
Other terminated trials from Hutchison Medipharma Limited
- Cancer · Phase PHASE1 · Dec 2018
- Crohn Disease · Phase PHASE1 · Nov 2018
- Solid Tumor · Phase PHASE1 · Aug 2018
- Ulcerative Colitis · Phase PHASE3 · Oct 2014
- Ulcerative Colitis · Phase PHASE3 · Oct 2014
More terminations from Hutchison Medipharma Limited
Other Acute Myeloid Leukemia trials with similar outcome
This PHASE1 trial investigates Acute Myeloid Leukemia and is currently terminated or withdrawn. Hutchison Medipharma Limited leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Nov 2022 [monthly]
Terminated PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
▶ Show 4 earlier versions
-
Nov 2018 — Dec 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hutchison Medipharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .